Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

NRXP

NRX Pharmaceuticals Inc

May 15 • 04:00PM ET

3.23

Dollar change +0.05
Percentage change 1.57	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI PSIL VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.11	Insider Own	17.80%	Shs Outstand	8.39M	Perf Week	14.54%
Market Cap	30.91M	Forward P/E	-	EPS next Y	-2.10	Insider Trans	0.00%	Shs Float	7.87M	Perf Month	-24.88%
Income	-25.65M	PEG	-	EPS next Q	-0.55	Inst Own	4.06%	Short Float	6.18%	Perf Quarter	-34.36%
Sales	0.00M	P/S	-	EPS this Y	45.50%	Inst Trans	-	Short Ratio	1.11	Perf Half Y	-3.73%
Book/sh	-1.54	P/B	-	EPS next Y	3.67%	ROA	-200.56%	Short Interest	0.49M	Perf Year	-53.63%
Cash/sh	0.14	P/C	23.42	EPS next 5Y	-	ROE	-682.61%	52W Range	1.90 - 12.00	Perf YTD	-29.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-73.08%	Beta	1.25
Dividend TTM	-	Quick Ratio	0.18	Sales past 5Y	0.00%	Gross Margin	-	52W Low	70.00%	ATR (14)	0.51
Dividend Ex-Date	-	Current Ratio	0.18	EPS Y/Y TTM	43.19%	Oper. Margin	0.00%	RSI (14)	47.51	Volatility	10.11% 14.76%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	50.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-350.73%	Payout	-	Rel Volume	0.42	Prev Close	3.18
Sales Surprise	-	EPS Surprise	4.00%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	438.26K	Price	3.23
SMA20	8.77%	SMA50	-25.81%	SMA200	-12.84%	Trades		Volume	182,108	Change	1.57%

May-14-24 08:57PM	NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) +6.35%
04:01PM	NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-08-24 09:55AM	NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update (ACCESSWIRE)
08:30AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 (PR Newswire)
May-07-24 04:01PM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024 (PR Newswire) -8.17%
08:30AM	Loading…
May-06-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression (PR Newswire) +45.71%
Apr-30-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression (PR Newswire) -27.32%
Apr-18-24 08:56AM	Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today? (InvestorPlace) -27.75%
08:32AM	NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement (PR Newswire)
08:30AM	NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock (PR Newswire)
Apr-17-24 04:45PM	NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire)
08:30AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections (PR Newswire)
Apr-15-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) (PR Newswire)
Apr-08-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression (PR Newswire)
Apr-04-24 12:00PM	NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +9.70%
10:33AM	Loading…
Apr-02-24 10:33AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-01-24 08:28AM	NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (PR Newswire) +11.25%
Mar-28-24 10:53PM	NRXP Stock Earnings: NRX Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace) -10.96%
08:03AM	NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights (PR Newswire)
08:00AM	NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing (PR Newswire)
Mar-26-24 04:03PM	UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 (PR Newswire)
Mar-25-24 08:30AM	NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK (PR Newswire) -5.36%
Mar-21-24 04:02PM	NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024 (PR Newswire)
01:57PM	NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders (PR Newswire)
Mar-18-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders (PR Newswire) +13.16%
Mar-12-24 07:49AM	NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales (PR Newswire) -34.32%
Mar-11-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) (PR Newswire) +9.06%
Mar-04-24 08:30AM	NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression (PR Newswire) +18.69%
Mar-01-24 08:30AM	NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share (PR Newswire) +22.03%
Feb-27-24 10:49AM	/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./ (PR Newswire) -31.24%
08:54AM	Loading…
08:54AM	NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million (PR Newswire)
08:31AM	Why Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today? (InvestorPlace)
Feb-26-24 04:01PM	NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire)
08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024 (PR Newswire)
Feb-20-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024 (PR Newswire)
Feb-12-24 08:30AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW) (PR Newswire) -6.25%
Feb-09-24 08:30AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report (PR Newswire) +10.34%
Feb-05-24 06:48AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon (PR Newswire) +5.28%
Jan-22-24 06:48AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression (PR Newswire)
Jan-17-24 06:48AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination (PR Newswire)
Jan-16-24 06:48AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis (PR Newswire)
Jan-02-24 08:45AM	NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco (PR Newswire) +8.48%
06:48AM	NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard (PR Newswire)
Dec-27-23 06:48AM	NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors (PR Newswire)
Dec-19-23 08:15AM	NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression (PR Newswire) -7.34%
Dec-18-23 06:48AM	NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections (PR Newswire) +24.19%
Dec-13-23 04:02PM	NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders (PR Newswire)
Dec-11-23 06:48AM	NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event (PR Newswire)
Nov-27-23 04:01PM	NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference (PR Newswire)
Nov-16-23 02:07PM	NRx Pharmaceuticals founder unveils potential treatment for suicidal thoughts and depression (News Direct) -6.86%
09:32AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 06:39PM	NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-07-23 06:48AM	NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023 (PR Newswire)
Nov-06-23 06:48AM	NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression (PR Newswire) +5.22%
Oct-31-23 06:48AM	NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression (PR Newswire)
Oct-26-23 06:48AM	NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain (PR Newswire) +6.71%
Oct-12-23 06:48AM	NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference (PR Newswire) +6.54%
Oct-05-23 06:48AM	NRx Pharmaceuticals to Present at 8th Annual Dawson James Conference (PR Newswire)
Oct-02-23 06:48AM	NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain (PR Newswire) +10.42%
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-20-23 06:47AM	NRx Pharmaceuticals Publishes Shareholder Update Letter (PR Newswire)
Sep-19-23 09:00AM	Sidoti Events, LLCs Virtual September Small-Cap Conference (ACCESSWIRE)
Sep-18-23 06:46AM	NRx Pharmaceuticals to Present at the Sidoti Virtual Small Cap Conference (PR Newswire) -9.72%
Sep-15-23 06:46AM	NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression (PR Newswire) +10.17%
Sep-14-23 04:01PM	NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support (PR Newswire)
Sep-07-23 06:47AM	NRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire) -8.24%
Sep-06-23 10:55AM	NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens (PR Newswire)
Aug-30-23 06:47AM	NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain (PR Newswire)
Aug-29-23 06:54AM	NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share (PR Newswire) +12.36%
Aug-14-23 04:01PM	NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-07-23 06:47AM	NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023 (PR Newswire) -6.46%
06:47AM	NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101 for Chronic Pain (PR Newswire)
Jun-20-23 04:01PM	NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (PR Newswire)
Jun-09-23 08:45AM	NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering (PR Newswire)
Jun-06-23 12:20PM	NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering (PR Newswire) -18.75%
Jun-02-23 02:19PM	NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023 (PR Newswire) +21.92%
May-16-23 06:47AM	NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -7.26%
May-10-23 04:05PM	NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call (PR Newswire)
Apr-27-23 04:01PM	NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023 (PR Newswire)
Mar-30-23 04:01PM	NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update (PR Newswire)
Mar-27-23 06:47AM	NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression (PR Newswire)
Mar-17-23 06:47AM	NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 (PR Newswire)
Mar-09-23 06:47AM	NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering (PR Newswire)
Feb-22-23 06:47AM	NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio (PR Newswire)
Feb-13-23 06:47AM	NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality (PR Newswire)
Feb-02-23 06:47AM	NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior (PR Newswire) +5.93%
Jan-19-23 06:47AM	NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101 (PR Newswire)
Jan-05-23 06:47AM	NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference (PR Newswire) -6.78%
Jan-03-23 06:47AM	NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted (PR Newswire) +9.01%
Dec-20-22 01:30AM	Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements (PR Newswire) +6.54%
Dec-05-22 06:47AM	NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs (PR Newswire)
Dec-02-22 06:47AM	NRx Receives Nasdaq Notice of Listing Compliance (PR Newswire) -6.76%
Nov-14-22 06:47AM	NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire) -9.99%
01:30AM	Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements (ACCESSWIRE)
Nov-10-22 06:47AM	NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022 (PR Newswire)
Nov-09-22 06:47AM	NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process (PR Newswire)
Nov-07-22 06:47AM	NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing (PR Newswire) +6.61%
Sep-08-22 06:40AM	NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference (PR Newswire) +10.53%
Aug-22-22 12:09PM	NRx, Relief Therapeutics reach tentative agreement to resolve litigation tied to Covid-19 therapy candidate (American City Business Journals)
06:00AM	RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION (PR Newswire)

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hurvitz Chaim	Director	Aug 30 '23	Buy	0.29	70,000	20,125	570,000	Sep 11 09:15 AM
Gorovitz Aaron	Director	Aug 30 '23	Buy	0.32	35,000	11,196	105,000	Sep 11 09:19 AM
Javitt Jonathan C	Chief Scientist	Aug 23 '23	Buy	0.33	100,000	33,000	446,332	Aug 24 12:14 PM
Javitt Jonathan C	Chief Scientist	Aug 22 '23	Buy	0.32	200,000	64,400	346,332	Aug 23 09:24 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRXP

NRX Pharmaceuticals Inc

Upgrade your FINVIZ experience